SLC5A2 and heart failure: Oxidative stress and inflammation are essential contributors to heart failure and renal failure, and diabetic cardiac remodeling is redox-sensitive (Nikolic et al. 2021; Pickering et al. 2018; Wilson et al. 2018). A low dose of SGLT2 inhibitor canagliflozin has a renal-protective effect independent of its glucose-lowering effect but may involve inhibition of high-glucose-induced DAG-PKC activation and ROS overproduction (Maki et al. 2019a).